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Genetic markers of the endocannabinoid system have been linked to a variety of
addiction-related behaviors that extend beyond cannabis use. In the current study we
investigate the relationship between endocannabinoid (eCB) genetic markers and alcohol
use disorder (AUD) in European adolescents (14–18 years old) followed in the IMAGEN
study (n= 2,051) and explore replication in a cohort of North American adolescents from
Canadian Saguenay Youth Study (SYS) (n = 772). Case-control status is represented
by a score of more than 7 on the Alcohol Use Disorder Identification Test (AUDIT).
First a set-based test method was used to examine if a relationship between the eCB
system and AUDIT case/control status exists at the gene level. Using only SNPs that
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are both independent and significantly associated to case-control status, we perform
Fisher’s exact test to determine SNP level odds ratios in relation to case-control status
and then perform logistic regressions as post-hoc analysis, while considering various
covariates. Generalizedmultifactor dimensionality reduction (GMDR) was used to analyze
themost robust SNP× SNP interaction of the five eCB genes with positive AUDIT screen.
While no gene-sets were significantly associated to AUDIT scores after correction for
multiple tests, in the case/control analysis, 7 SNPs were significantly associated with
AUDIT scores of > 7 (p < 0.05; OR<1). Two SNPs remain significant after correction
by false discovery rate (FDR): rs9343525 in CNR1 (pcorrected =0.042, OR = 0.73) and
rs507961 in MGLL (pcorrected = 0.043, OR = 0.78). Logistic regression showed that
both rs9353525 (CNR1) and rs507961 (MGLL) remained significantly associated with
positive AUDIT screens (p < 0.01; OR < 1) after correction for multiple covariables and
interaction of covariable x SNP. This result was not replicated in the SYS cohort. The
GMDRmodel revealed a significant three-SNP interaction (p= 0.006) involving rs484061
(MGLL), rs4963307 (DAGLA), and rs7766029 (CNR1) predicted case-control status, after
correcting for multiple covariables in the IMAGEN sample. A binomial logistic regression
of the combination of these three SNPs by phenotype in the SYS cohort showed a
result in the same direction as seen in the IMAGEN cohort (BETA = 0.501, p = 0.06).
While preliminary, the present study suggests that the eCB system may play a role in the
development of AUD in adolescents.
Keywords: alcohol use disorder, cannabinoid receptor 1, CNR1, DAGL, endocannabinoid system, MGLL
INTRODUCTION
Substance use disorders are a growing concern across the world,
with an estimated 31 million users worldwide suffering from
drug use disorders. After alcohol and tobacco, cannabis ranks
as the most used drug worldwide (1). Moreover, those who use
cannabis are more than five times more likely to have an alcohol
use disorder (AUD) (2). Considering that the endocannabinoid
(eCB) system is responsible for the physiological consequence
and subjective “high” of cannabis, much attention has been
paid to the eCB role in the development of various substance
use disorders. Cannabinoid receptors and related enzymes are
expressed in many of the reward centers of the brain: nucleus
accumbens (NAc), ventral tegmental area (VTA), amygdala, and
basal nucleus of the stria terminalis (BNST) (3, 4). These eCB
levels are affected by ethanol (5), and the eCB system plays a role
in the development of AUD and other substance use disorders in
humans (4). Basavarajappa and colleagues (6) demonstrated that
acute ethanol use has been associated with an increase in eCB
signaling, while others have reported that alcohol use decreases
eCB signaling (7, 8). Moreover, as is the case with other drugs of
abuse, eCBs mediate the reward signals associated with alcohol
use (9). Overall, the underlying evidence shows that the eCB
system is modulated by ethanol use, and this same system may
play an independent role in AUD (10).
The first eCB receptor isolated, of which tetrahydrocannabinol
(THC) is also a ligand, is the cannabinoid receptor one (CB1)
(11, 12). Binding to this receptor and a second cannabinoid
receptor (CB2) are the two main eCB agonists, anandamide
(AEA) and 2-arachidonoylglycerol (2-AG). These agonists—
which are not stored in vesicles—are produced through an
enzymatic cascade in a Ca22++ dependent manner, and then
are rapidly degraded by specific enzymes, fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MAGL). N-
acylphosphatidylethanolamine-specific phospholipase D (NAPE-
PLD) plays a crucial role in the synthesis of AEA, which then
binds to CB1. 2-AG is synthesized by diaglycerol lipase (DAGL).
It has been shown that polymorphisms in the CNR1 gene, the
gene coding for the CB1 receptor protein, are associated with a
range of diseases, psychiatric disorders, and substance use (13–
15). Many studies have assessed the various aspects of the eCB
genes and their relationship with substance use disorders and
risk-taking behavior. The single nucleotide polymorphism (SNP)
rs1049353 in the CNR1 gene has been associated with severe
alcoholism (minor A allele) (16), heroin addiction (major G
allele) (17), and impulsivity (18). Furthermore, haplotype blocks
within the CNR1 gene have been associated with addiction and
addictive behavior (19, 20). Polymorphisms in the FAAH gene
have also been associated with problem drug use and addiction
(21, 22). In contrast, there have been relatively few studies
examining the MGLL gene, the gene coding for the MAGL
enzyme, and theDAGL in association with drug dependence (23–
25). Among these, only one study has found a positive association
between SNPs of the MGLL gene and drug dependence (25),
while no studies have reported a significant association between
DAGL and any form of drug abuse. Moreover, many of the
original findings reporting an association between SNPs located
in genes of the eCB and various drug abuse behaviors have not
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been replicated (4, 26), suggesting the possibility of false positive
results in these candidate gene approaches. Nevertheless, while
there are conflicting results among studies, the candidate gene
literature suggests that genes related eCB proteins may play a role
in the development of substance use problems.
While candidate gene findings in psychiatric genetics have
been widely criticized for replication failure, particularly with
respect to GWAS and meta-analysis (27), candidate gene
approaches in addiction research have identified genetic markers
that have been confirmed in GWAS and meta-analysis (28). This
is perhaps related to particularly heritable nature of addictive
behaviors compared to other psychiatric conditions, or to the
fact that candidate gene approaches can be directly informed
by pharmacogenetic studies on how drugs of abuse interact
with the brain’s neurochemistry. Others have argued (29) that
the failure to replicate candidate gene findings through GWAS
and meta-analysis does not necessarily suggest the findings are
false. The candidate gene findings may represent particular
endophenotypes of sub-populations, which may account for a
portion, albeit small, of genetic influence on the phenotype in
question. Thus, other groups have utilized novel methodologies,
such as gene-set approaches, to analyze hypothesis-based
questions in psychiatric genetics and addiction medicine.
Recently, one group, utilizing said gene-set approaches, found
that MGLL and the SNP rs604300 interact with childhood
sexual abuse to predict cannabis dependence symptoms (25).
Considering our relatively limited understanding of the roles
of the various endocannabinoid genes in the pathogenesis of
addictive behaviors, and the lack of robust findings at the
individual SNP, or GWAS levels, gene-set, and system-based
approaches remain of interest (25, 30). Thus, the current study
employs a gene-set based approach in an attempt to shed
light on the role of the eCB system in the pathogenesis of
addictive behaviors.
Given the effect of alcohol on the eCB system (5) and the
purported relationship between eCB SNPs and the risk for
substance use disorder, we assessed the association between
eCB genetics and alcohol abuse behaviors in the IMAGEN
cohort (31). The IMAGEN cohort is a European cohort of 2,087
adolescents recruited in France, UK, Ireland, and Germany.
Endocannabinoid genetic influence was studied through a
candidate gene approach. Multiple SNPs in eCB genes that have
been previously examined (CNR1, FAAH, MAGL, DAGLA) as
well as genes that have not yet been investigated (NAPEPLD)
were analyzed in the context of alcohol use disorder (AUD).
To understand this relationship, a three-tiered approach was
used. First, a set-based test (32) is utilized to study, at the
gene level, the link between the eCB system and alcohol
abuse behavior. Through this approach we also identify SNPs
that are significantly and independently associated to positive
AUD screening, and these SNPs are selected for further study
using a case/control analysis and subsequent logistic regression.
Finally, while some studies have investigated the interaction
between two eCB genes and addictive behavior (33, 34), none
have examined the eCB system as a whole. Considering the
complex interplay between the multiple eCB ligands (AEA and
2-AG among others) and various receptors (CB1, CB2, etc.)
in their relationship to addictions (4), we hypothesize that
a single genetic marker association study could not account
adequately for the multifaceted role the eCB system plays in
risk for AUD. A new wave of candidate gene studies have
explored more complex gene-gene interactions, using various
methods of multifactor dimensionality reductions analyses to
yield promising results such as predicting outcomes in breast
cancer treatment (35), in determining genetic biomarkers to
predict antidepressant response (36), and further understanding
the genetic influences of nicotine addiction (37). Here, we utilized
Generalized Multifactor Dimensionality Reduction (GMDR) to
understand the effects that the multiple eCB genes may have on
each other and their combined influence on alcoholic behavior
in adolescence. To replicate the results, genetic and alcohol
use data were used from the Saguenay Youth Study (SYS), a
two-generational study comprised of 1,029 French-Canadian
adolescents and their parents.
MATERIALS AND METHODS
Participants
The IMAGEN study is a longitudinal imaging genetics study of
2,087 healthy adolescents, mostly of European descent. Detailed
descriptions of this study, genotyping procedures, and data
collection have previously been published (31). The IMAGEN
cohort has been repeatedly assessed on substance use outcomes
at 14, 16, and 18 years of age. The multicentric IMAGEN project
had obtained ethical approval by the local ethics committees
(at their respective sites) and written informed consent from
all participants and their legal guardians. The parents and
adolescents provided written informed consent and assent,
respectively. All datasets were de-identified by using codes
for individuals. See Schumann et al. (31) for a more detailed
description of the IMAGEN cohort.
The current study used data for all 2,087 individuals who
completed the IMAGEN assessment battery at 14, 16, and 18
years of age and who contributed their genetic data at 14 years of
age. Of those followed at 16 or 18 years of age, three individuals
had unassigned sex according to sex determination analysis
in PLINK1.9 (38) and were thus excluded from the genetic
analyses. Moreover, 11 individuals did not answer the Alcohol
Use Disorder Identification Test (AUDIT) at any time point and
were thus removed from the genetic analyses. Eleven pairs of
siblings were a part of the IMAGEN database, and thus one
sibling from each pair was removed from the study, according to
the methods published (39). European ancestry was determined
using Admixture (40) using HapMap III (41) as a reference
population. Eleven individuals with non-European ancestry were
removed prior to analysis. Thus, in this study there was a total of
1,043 female and 1,008 males. A summary of the individuals can
be seen in Table 1 and Supplementary Table 1.
Phenotype Evaluated
Alcohol Misuse
AUDIT is a self-report questionnaire developed by the World
Health Organization and validated (42) to screen for heavy
drinking and current alcohol dependence. Individuals were
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TABLE 1 | Description of subjects in IMAGEN and SYS.
Cohort IMAGEN SYS
N (female %) 2051 (50.8%) 772 (52.07%)
N family 2051 401
Age (SD) 14 to 18 yearsc 15 years (1.85)
AUDITa Control 1476 -
Case 575 -
GRIPb Control - 724
Case - 48
a IMAGEN subjects are classified by status with AUDIT score, case is > or = to 8 and
control < 8; bSYS subjects are classified by status with GRIP score, case > or = to 2 and
control < 2. c IMAGEN cohort is a longitudinal cohort, so it’s not possible to calculate the
standard deviation (SD).
considered to screen positive for risk for AUD and were included
in the case group if they scored 8 or more on the AUDIT
(case-control status). While other studies focusing on adolescent
alcohol abuse used a less stringent cut-off (43–45), the more
stringent cut-off of 8 was chosen as this is the cut-off with the
strongest sensitivity and a favorable specificity across all studies
(46). Four AUD scores were derived: “Any AUD” representing
having screened positive for AUD at any timepoint from 14–18
years of age, and then individual dichotomized scores for each of
the time points, 14, 16, and 18 years. For details about choice of
cut-off, see Supplementary Methods.
Covariates
Covariables include sex, the first six genetic principal
components, parental alcohol abuse, and parental education.
Parental education was taken from the parent-report
questionnaire using the educational categories specified in
the European School Survey Project on Alcohol and Other
Drugs (ESPAD+) questionnaire. Risk for AUD in parents was
measured using the AUDIT obtained at the first two time
points in IMAGEN. If ESPAD+ and AUDIT information were
missing at the 18-year-old time point, the most complete and
recent information was used at this time point. If a parent had
signaled a positive AUDIT at any time, they were flagged as such.
Moreover, if parental information was missing, individuals were
not included in the logistic regression.
Pipeline of SNP Selection
The genotyping was run using the Illumina Quad 610 chip
and 660Wq at the “Centre National de Genotypage” (Paris,
France). Only autosomal SNPs were kept for this study. SNPs
with a minor allele frequency (MAF) of <5%, a missing SNP
rate of 10%, or SNPs that did not respect Hardy Weinberg
Equilibrium (HWE) (<1 × 10−6) were also removed from this
study. All available SNPs in the genes of interest (CNR1, NAPE,
FAAH, MGLL, DAGLA) within±10 kb (to include promoter and
flanker regions) were then selected. Gene length and location
were obtained using the UCSC Genome Browser. The SNP
coordinates were updated from hg18 to hg19 using Illumina
information and the liftover tool from the genome browser
(http://genome.ucsc.edu/cgi-bin/hgLiftOver). Nevertheless, SNP
information was scarce on the CNR2, and as such, the gene was
not included in this study. A summary of the locations and details
of each SNP (gene, chromosome, base pair, function, etc.) can be
seen in Supplementary Table 2.
Statistical Analysis
Sixty-nine SNPs appearing across five cannabinoid-related
genes were analyzed for their relation to problematic alcohol
consumption. As a primary analysis, we first conduct three set-
based tests using parameters of varying stringencies, to study
the relationship between 5 endocannabinoid gene-sets (CNR1,
NAPEPLE, FAAH, MGLL, DAGLA). The parameters that were
adjusted between the tests were p-value for significant variants
between tests, r2 of variant pairs, and maximum set size. Data
in all three set-based tests underwent 10,000 label-swapped
permutation as well, using the—perm function in PLINK1.9. The
first test was the default test in PLINK1.9, with a p-value of 0.05,
r2 of 0.5, and a set-max of 5; the second test had a p-value of
0.05, r2 of 0.3, and set-max of 3; while test 3 had a p of 0.01, r2
of 0.1, and set-max of 2. Tests 2 and 3 were more stringent and
were run to challenge the data, to ensure robustness of our results.
Statistical significance for set-based test was determined using
a Bonferroni corrected empirical p-values of p < 0.01 (0.05/5
genes). Burden and optimized sequence kernel association tests
(SKAT, R package) (47) were used to analyze the joint effects
of SNPs (in gene sets). These analyses were performed on three
groups of variants: (a) Set 1, (b) Set 2, (c) Set 3 defined with
gene set PLINK analyses. We resampled 10,000 times to compute
empirical p-values (p-values were adjusted controlling for family-
wise error rate) for the analyses (with “bootstrap” option).
Next, to determine SNP level odds ratios (OR) case-control
analysis was run on the SNPs that were nominally significant
and independent after set-based analysis, using Fisher’s exact
test. In the case-control analysis, false discovery rate (FDR) was
used to correct for multiple tests. To test the robustness of
these findings after controlling for various relevant covariates,
a logistic regression was performed that included only the SNPs
that remained significant after correction for multiple tests, sex,
the first six ancestry components, parental AUDIT flag, and
parental education were included in the logistic model. In post-
hoc analysis, for SNPs that significantly predicted case-control
status, after controlling for covariates, we control for potential
confounding of interaction (48) and include the interaction of
the covariate of no interest by SNP (see Supplementary Methods
for descriptions of the covariables and Supplementary Figure 1
for results of principal component analysis). The set-based test,




In order to test the replicability of these findings across a different
analytic strategy, GMDRwas employed to analyze the SNP x SNP
interaction with phenotype. GMDR (v1.0) is a free open source
tool for identification of interactions, developed by Guo-Bo Chen
(49). This program was used to screen for the best interaction
combinations among the 69 SNPs and the phenotype of interest.
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Permutation with 10,000 shuffles providing empirical p-values to
measure the significance of an identified model was used. For
these analyses, logistic regression with the same covariables as
described above were performed. For more information on the
GMDR method see Lou et al. (49).
SYS Replication Cohort
Genetic and alcohol-use data from the Saguenay Youth Study
(SYS) were used to replicate the findings. The SYS is a two-
generational study comprised of 1,029 adolescents and 962
parents (50). For descriptive characteristics of the participants
included in the replication see Supplementary Table 3 and
Table 1. All individuals were genotyped using whole blood
samples from which DNA was extracted. The genotyping was
performed at “Centre Nationale de Génotypage” for 610Kq
(No. arrays = 599) and at the Genome Analysis Centre of
Helmholtz Zentrum München (Munich, Germany) for HOE-
V12 (No.arrays = 1,395). Genetic information was imputed
following previously published methods (50) and after that, the
69 SNPs studied were extracted. Detailed descriptions of the
cohort, genotyping, and data collection have previously been
published (50, 51).
Participants were recruited over a 10-year period. Once
recruited, adolescents provided genetic material and underwent
a detailed assessment in several domains. Alcohol-use data for
the SYS cohort were obtained via a self-report questionnaire
developed specifically for the SYS to assess mental health and
substance use based on validated protocols (52). The items from
this questionnaire that were deemed to overlap sufficiently with
AUDIT questions are listed in Supplementary Table 4. Of 1,029
adolescents in the SYS cohort, 772 adolescents aged 14 years
and older had completed both the SUD assessment and provided
genetic information, and were therefore included in this study.
In the replication of the case-control study, we studied the
7 SNPs found in the set-based test. Description of SNPs can
be found in Supplementary Table 5. Two statistical models
were used to study the replication group. To study the native
continuous phenotype, a model based on the quasi-poisson
distribution was used. The participants were also separated into
four different drinking groups, based on scoring distribution. A
binomial logistic model was then used separating the participants
into controls (groups 0–1; low alcohol use) and cases (groups
2–4; high alcohol use). Both models considered sex, age as
covariables and family ID as random effect. Statistical analyses
were performed using R, with the glmmTMB library, version
3.5.3 (https://www.R-project.org/).
RESULTS
Set-Based Tests: Identifying Candidate
SNP
The three set-based tests were run, with varying results
(Supplementary Table 6). In the first set-based test, nine SNPS
returned with nominal p-values of <0.05, of which seven also
passed linkage disequilibrium (LD) criterion. Through the first
set-test criterion, only the CNR1 gene-set had a significant
empirical p-value (p = 0.022), but this was not significant after
correction for multiple tests. Within this set, only rs9353525 was
significantly and independently related to dichotomized AUDIT
scores. In the second set-based test, the same nine SNPS returned
with nominal p-values of<0.05, of which five SNPs passed the LD
criterion. Nonetheless, no gene sets were significantly associated
to case control status (p > 0.05). Finally, four SNPs returned
with a p-value < 0.01 in the third test, with two SNPs passing
LD criterion. No genes remained significant after correction for
multiple testing (pFDR > 0.05). As mentioned above, the seven
SNPs that had marginal p-values of <0.01 in the first set-based
test, and that passed LD criterion (r2 < 0.5), were extracted, and
only these were analyzed in the case-control analysis and logistic
regression analysis. SKAT demonstrated similar results for the
CNR1 gene (Supplementary Table 7).
Case-Control Analysis and Sensitivity
Analysis
In the case-control analysis of the IMAGEN cohort, which
considered cases as individuals who scored eight or more on
AUDIT at any time point (ALL), all 7 SNPs analyzed were
significant (p < 0.05) (Table 2). All of the minor alleles were
protective against having a case control status (OR < 1). Two
SNPs remained significant after correction by FDR: rs9343525
in CNR1 (pFDR = 0.043, OR = 0.73) and rs507961 in MGLL
(pFDR = 0.043, OR = 0.78). A multivariate logistic regression
analysis was done for the two SNPs that were significant after
FDR correction in the Fisher test (Table 3). As a first post-hoc
analysis logistic models were done for significant SNPs, at each
time point (14, 16, and 18), as well as for any positive screen
(ALL) for case-control status. After controlling for the effects of
the first six principal components, sex, parental AUDIT scores (at
any time), and parental education, both rs9353525 and rs507961
were still significantly associated with positive AUDIT screen in
the ALL analysis (Table 3) (p < 0.01), with both SNPs minor
allele acting as protective factors (OR < 1). In our post-hoc
analysis, we find a significant interaction between rs9353525 and
PC1 and PC6, as well as a significant interaction of rs507961 and
PC3, suggesting that the genetic background, captured by the
principal components, maymodify the genetic effects of the SNPs
on AUDIT scores. For complete results of logistic regression
see Supplementary Table 9, and see Supplementary Table 10 for
results of post-hoc interaction analyses. Finally, we conducted post
hoc analyses to study the association between AUDIT scores and
SNPs of interest at each IMAGEN time point (14, 16, and 18
alone). After correction for multiple testing, none of the post-
hoc analysis demonstrated significant results (see Supplementary
Results for detailed results).
In the replication cohort, rs484061 was significantly associated
with problematic alcohol use (p = 7.47∗10−6) in the binomial
model. None of the other SNPs in the replication analysis
had a significant result, after correction for multiple tests
(Supplementary Table 8).
GMDR: SNP × SNP Interactions
A GMDR model was used to screen for the most robust
interaction of combinations for the 69 SNPs in the candidate
genes and case control status. For the one and two-SNP
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TABLE 2 | Table of results for case/control analysis ALL.
SNP A1 A2 Freq AC Freq AU OR Pvalue FDR Pvalue
rs782446 C A 0.22 0.26 0.83 0.024 0.081
rs484061 G A 0.46 0.51 0.83 0.0091 0.055
rs604300 A G 0.09 0.11 0.77 0.033 0.085
rs507961 T C 0.20 0.24 0.78 0.0047 0.043
rs9353525 A G 0.10 0.14 0.73 0.004 0.043
rs4729873 G A 0.33 0.38 0.85 0.027 0.081
rs10488693 T C 0.06 0.08 0.73 0.026 0.081
A1, minor allele; A2, major allele; Freq AC, frequency of minor allele in cases; Freq AU,
frequency of minor allele in controls; OR, odds ratio. FDR Pvalue, p-value after false
discovery rate correction.
TABLE 3 | Table of results for logistic model with AUDIT and rs9353525
and rs507961.
Phenotype SNP A1 NMISS BETA OR STAT P
AUDIT ALL rs507961 T 2030 −0.27 0.76 −3.06 0.002
rs9353525 A 2026 −0.30 0.74 −2.61 0.009
AUDIT for 14 rs507961 T 2024 −0.24 0.78 −1.10 0.27
rs9353525 A 2020 −0.22 0.81 −0.78 0.44
AUDIT for 16 rs507961 T 1535 −0.19 0.83 −1.49 0.14
rs9353525 A 1532 −0.46 0.63 −2.49 0.01
AUDIT for 18 rs507961 T 1243 −0.30 0.74 −2.59 0.01
rs9353525 A 1240 −0.32 0.73 −2.05 0.04
A1, minor allele. NMISS, number of non-missing individuals. OR, odds ratio. Stat,
coefficient t-statistic. p < 0.05.






Sign test (p) CV
consistency
[rs806368] 0.53 0.49 8 (0.94) 15/20
[rs806368,
rs10488693]




0.58 0.541 16 (0.006) 19/20
Model, SNPs included in the model; Sign test, sign test result with p-value in parentheses;
CV consistency, cross validation consistency.
models, no significance was found p>0.05. However, we
found a significant three-SNP model (p = 0.006) involving
rs484061 (MGLL, intron), rs4963307 (DAGLA, intron), and
rs7766029 (CNR1, downstream-gene) with AUDIT positive
screens. An interaction between rs484061, rs4963307, and
rs7766029 was significantly associated with case-control status,
with a combination of G/A;G/A;C/C or G/G;G/G;C/C conferring
protection against problem drinking in the cohort (p = 0.004
and p = 0.02, respectively; Supplementary Table 11). The cross-
validation consistency of this three-locus model was 19/20. The
testing accuracy of the three SNP model (54%) was greater
than the testing accuracy of either the one SNP (49%) or
two SNP models (50%) (Table 4 and Figure 1). This result
was verified by re-analyzing the model using 10 different
random seeds, and this model remained significant for each
seed. An analysis of the same three SNP combination in
the SYS cohort, binomial logistic model, showed a result in
the same direction as seen in the IMAGEN cohort (BETA
= 0.50, p = 0.06), and the distribution of at risk and
protective combinations of SNP with phenotype is comparable
to that of the IMAGEN population (Supplementary Tables 11,
12).
DISCUSSION
Although no gene-sets were significantly predictive of
binary AUDIT scores, after correction for multiple tests,
our case/control analysis suggest that two SNPs, rs507961
(MGLL) and rs9343525 (CNR1), are associated with problem
drinking and remained significantly associated after correction
for multiple tests. The SNPs remained significantly associated
to case-control status in logistic regression, while considering
multiple covariables, and the interaction of these covariables
and the SNPs in question. The results of our logistic regression
were not replicated in the replication cohort. To our knowledge,
one study (25) had investigated rs507961 in MGLL in relation
to substance use disorders; however, the association did not
remain significant after correction for multiple tests. While
rs507961 is intronic in MGLL, this SNP plays a role in histone
regulation of this gene in the brain (Supplementary Table 13).
The robustness of our result confers evidence that carrying the
minor T allele may in fact confer protection against problem
drinking. Moreover, no study has investigated the relationship
between rs484061, another MGLL SNP, and substance use
disorders. The recurrence of rs484061 in both the GMDR
model and case-control analyses suggests that being a carrier
of this SNP protects against risk for AUD. While rs484061
was significantly associated to positive AUDIT screens in the
case-control analysis of the IMAGEN cohort (p= 0.009, pFDR=
0.055) and replicated in SYS (p = 7.47∗10−6), it was significantly
associated to lower alcohol use. Our results suggest a role for
MGLL in AUD but work in larger cohorts is needed to confirm
this result.
The second SNP that remained significant after correction
for multiple tests in our case-control analysis was rs9353525.
It is localized in an intergenic region <10Kb of the 3′ region
of CNR1. In an attempt to understand the biological role
that this SNP plays in the regulation of CNR1 expression,
we scanned the various available databases for potential roles;
however, this SNP is relatively understudied. While this SNP
was not associated with higher rates of alcohol use in the
SYS cohort, this SNP is in strong linkage disequilibrium with
rs806368 (at 78% for allele T with G respectively for rs806368
and rs9353525). The rs806368 has been associated to alcohol
dependence in other studies (53). We also investigated rs806368
in our cohort, using the same case-control analysis as for our
other SNPs, and the major allele is associated with likelihood of
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FIGURE 1 | Illustration for the best combination defined by GMDR for 69 SNPs for AUDIT. The allele code is defined by minor allele numbers of rs484061 (allele G),
rs4963307(allele A) and rs7766029 (allele T). The numbers above the histogram bar, indicate the sum of “positive” (above the averaged score = 0) and “negative”
(below the averaged score = 0) scores by the combination of genotypes. Also, the dark gray indicates a high-risk combination of the genotypes with alcoholism and
light gray for low risk. It defined by sum of positive and negative score, when it’s < 0 for low-risk and > 0 for high-risk.
reporting a clinically significant AUDIT score at any timepoint
in the IMAGEN cohort (p = 0.007 OR = 1.28). Moreover,
this result remains significant after controlling for the various
covariates described above in the IMAGEN cohort (p = 0.007;
see Supplementary Tables 14, 15). Taken together, these results
suggest that the haplotype block containing both of the major
alleles of rs9353525 and rs806368 plays a role in the development
of AUD in adolescents.
A GMDR model was used to screen for the gene x gene
interaction that would be most associated to problem drinking,
across genes showing a signal in previous analyses. We found
a significant interaction involving rs484061 (MGLL), rs4963307
(DAGLA), and rs7766029 (CNR1) that predicted clinically
significant AUDIT scores after correction for covariates. Each
of these three SNPs are associated to loci, which are key
regulators of gene expression (Supplementary Tables 13, 16).
This observation was supported by the consistency of the
result in the GMDR, across IMAGEN and SYS GMDR results
(p = 0.06) (Supplementary Table 8). The similar distribution
pattern of problem drinkers within the SYS cohort suggests
that the marginal result in the SYS cohort is probably due
to a lack of statistical power. The SYS cohort comprises
a relatively young sample (mean age = 15 years old), as
compared to the IMAGEN cohort, which includes data from
individuals when they are 14, 16, and 18 years of age. As
such, many of the participants in the SYS cohort have not
had their first contact with alcohol, and therefore might not
have developed heavy patterns of drinking. This marginal
effect should be investigated using data from this sample as
it ages, to explore whether the effect becomes larger and
more significant when substance use behaviors are assessed
during the typical age when substance use disorders have
their onset.
Endocannabinoid Interactions in the Brain
and Emotional Regulation
The GMDR analysis suggests that a certain combination of SNPs
along the CNR1-DAGLA-MGLL genes protect against or pose a
risk for alcoholism, by presumably modulating DAGLA and or
MGLL expression and subsequently 2-AG levels. The DAGLA
protein (encoded by DAGLA) catalyzes the formation of 2-AG,
which then acts as an agonist of CB1. Then, 2-AG is promptly
degraded by MAGL (encoded by MGLL). Also, 2-AG has been
shown to play a key role in the regulation of the hypothalamic-
pituitary-adrenal (HPA) stress response axis (54), which is
altered in alcohol addiction (55). In response to increased
corticosterone, 2-AG levels increase in the medial prefrontal
cortex and paraventricular nucleus of the hypothalamus, and
act as a negative feedback signal to inhibit the HPA axis and
terminate the acute stress response (54). While 2-AG levels
increase in situations of chronic stress, it is theorized to play a
role in stress habituation (54). Along the same line, 2-AG has
also been shown to play a role in the reduction of stress induced-
anxiety in a role mediated through the actions of MAGL and
DAGLA (54). MAGL antagonists have been shown to have a
strong anxiolytic effect in rodents (56, 57). Knockout studies have
shown that DAGLA (-/-) mice, which have large reductions in
brain 2-AG levels, have increased anxiety-like symptoms (58,
59). Moreover, the anxiety-like state seen in animal models of
alcohol dependence and withdrawal symptoms are mediated by
corticosterone-releasing factor release in the central nucleus of
the amygdala (CeA) (60). A recent study in alcohol dependent
rodents found that 2-AG levels were decreased in the CeA of
these animal models, and that inhibition of MAGL, increasing 2-
AG levels, ameliorated abstinence-related anxiety and excessive
alcohol intake (61). Mice exposed to chronic mild stress have
reduced levels of DAGLA expression, and reduced DAGLA
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expression in this same study was significantly associated to
increased preference for alcohol (62). The study by Ishiguro and
colleagues was also the first to link SNPs in the DAGLA gene and
alcoholism in humans (62). Our study supports the hypothesis
that suggests that the eCB system plays a role in the development
and/or maintenance of AUD in adolescents. Previous findings
suggest that this vulnerability might be achieved by affecting
sensitivity to anxiety-like symptoms and influencing reward
sensitivity to alcohol intake and warrants further study.
While the results of this study suggest a relationship between
eCB genes and AUD, wemust acknowledge that the results of this
study are preliminary and modest. First, many researchers have
called hypothesis-based candidate gene approaches into question
(27, 63, 64). This is due to the fact that, while very large GWAS
studies consistently report that individual SNPs exert very small
effects on complex phenotypes such as addiction, most published
studies in the field report significant results, even with relatively
small sample sizes (27). Considering that these small candidate
gene studies may be underpowered (65, 66) (including ours),
the significant results reported in the past are most likely false
positive (27). It is also possible that this might be the case in the
current study; however, the use of a replication sample provides a
context in which to interpret the findings and make conclusions
about generalizability of the findings.
Moreover, we were unable to replicate many of the previously
reported findings in relation to substance use and eCB genes. This
is because our set-based test eliminated many of the previously
reported SNPs as they were non-independent according to our
criteria. Moreover, some SNPs that are previously reported,
mainly rs2023239 (9, 34) and rs6454674 (53, 67, 68), are not
assessed in the assay chips used in the present study or were
too infrequent in our cohort for analysis. This was also the
case for SNPs within CNR2 that have been previously evaluated
for their relationships with substance use. Considering that our
findings were most robust within the analysis considering all
timepoints, we cannot be certain what role these SNPs play in
the development of AUD (initiation of drinking, susceptibility
to binge drinking, proneness toward harmful alcohol use or
maintenance of abuse habits, etc.). Our findings suggest a
more robust relationship at later time points, potentially related
to the power that increased prevalence of AUD at the older
age affords in a statistical analysis. However, it will also be
important to investigate whether these genetic markers are
linked to maintenance of drinking in adults, relative to early
initiation behaviors, using larger longitudinal cohorts, when they
become available. Finally, there are limitations with the cohort
used for this study. Considering that our cohort is population-
based sample of adolescents, the number of problem drinkers is
relatively low. Moreover, as the cohorts aged, they reduced in size
due to participants leaving the study, diminishing the power of
the analyses. Finally, while the results of our replication study
were in line with the results of the IMAGEN analysis, our main
findings were not significant according to classic standards (p
= 0.05).
Nevertheless, the present suggests an interaction among
various candidate genes relevant to the eCB system in predicting
AUD, specifically the CNR1-MGLL-DAGL loop and their
relationship to 2-AG. Further studies are required to further
explore the generalizability of these findings and to understand
the psychiatric implications of the results.
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